GSK3B and pancreatic neoplasm: Notably, activation of the AKT/Gsk-3β/β-catenin pathway may contribute to gemcitabine resistance of human pancreatic cancer cells, in which the MDR1 gene acts downstream of β-catenin, and P-gp expression is upregulated [34, 35].